- Home
- NLSP vs PRPO Comparison
NLSP vs PRPO Comparison
Compare NLSP & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- PRPO
- Stock Information
- Founded
- NLSP 2015
- PRPO N/A
- Country
- NLSP Switzerland
- PRPO United States
- Employees
- NLSP N/A
- PRPO N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- NLSP Health Care
- PRPO Industrials
- Exchange
- NLSP Nasdaq
- PRPO Nasdaq
- Market Cap
- NLSP 12.4M
- PRPO 17.1M
- IPO Year
- NLSP 2021
- PRPO N/A
- Fundamental
- Price
- NLSP $2.10
- PRPO $15.75
- Analyst Decision
- NLSP
- PRPO
- Analyst Count
- NLSP 0
- PRPO 0
- Target Price
- NLSP N/A
- PRPO N/A
- AVG Volume (30 Days)
- NLSP 275.3K
- PRPO 16.2K
- Earning Date
- NLSP 07-22-2025
- PRPO 08-12-2025
- Dividend Yield
- NLSP N/A
- PRPO N/A
- EPS Growth
- NLSP N/A
- PRPO N/A
- EPS
- NLSP N/A
- PRPO N/A
- Revenue
- NLSP N/A
- PRPO $20,029,000.00
- Revenue This Year
- NLSP N/A
- PRPO N/A
- Revenue Next Year
- NLSP N/A
- PRPO N/A
- P/E Ratio
- NLSP N/A
- PRPO N/A
- Revenue Growth
- NLSP N/A
- PRPO 26.67
- 52 Week Low
- NLSP $1.30
- PRPO $3.90
- 52 Week High
- NLSP $15.59
- PRPO $16.89
- Technical
- Relative Strength Index (RSI)
- NLSP 46.61
- PRPO 76.66
- Support Level
- NLSP $2.20
- PRPO $10.60
- Resistance Level
- NLSP $3.08
- PRPO $11.70
- Average True Range (ATR)
- NLSP 0.25
- PRPO 0.97
- MACD
- NLSP -0.06
- PRPO 0.45
- Stochastic Oscillator
- NLSP 8.40
- PRPO 81.25
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.